logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 8846910 B1

PDFFull Text
Date of Patent:
Sep. 30, 2014

Filed:

Jul. 08, 2013

Matrix metalloproteinase inhibitors

Applicant:

Ranbaxy Laboratories Limited, Delhi, IN;

Inventors:

Viswajanani J. Sattigeri, Gurgaon, IN;

Venkata P. Palle, Pune, IN;

Manoj Kumar Khera, Gurgaon, IN;

Ranadheer Reddy, Suryapet, IN;

Manoj Kumar Tiwari, Mumbai, IN;

Ajay Soni, New Delhi, IN;

Abdul Rehman Abdul Rauf, Buldane, IN;

Sony Joseph, Ernakulam, IN;

Arpita Musib, Bankura, IN;

Sunanda G. Dastidar, New Delhi, IN;

Punit Kumar Srivastava, Gurgaon, IN;

Assignee:

Ranbaxy Laboratories Limited, New Delhi, IN;

Attorney:
Primary Examiner:

Venkataraman Balasubramanian

Int. Cl.
CPC ...
C07D 253/08 (2006.01); A61K 31/53 (2006.01); A61P 19/02 (2006.01); A61K 31/502 (2006.01); A61K 31/41 (2006.01); A61K 31/517 (2006.01); C07D 401/14 (2006.01); C07D 401/10 (2006.01); C07D 401/06 (2006.01); C07D 209/48 (2006.01); C07D 409/06 (2006.01); A61K 31/4155 (2006.01); C07D 209/44 (2006.01); C07D 405/10 (2006.01); A61K 31/438 (2006.01); C07D 413/10 (2006.01); A61K 31/444 (2006.01); A61K 31/536 (2006.01); A61K 31/506 (2006.01); C07D 403/10 (2006.01); C07D 409/10 (2006.01); A61K 31/4439 (2006.01); A61K 31/4035 (2006.01); A61K 45/06 (2006.01); C07D 409/14 (2006.01); C07D 265/26 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4155 (2013.01); A61K 31/502 (2013.01); A61K 31/41 (2013.01); A61K 31/517 (2013.01); C07D 401/14 (2013.01); C07D 401/10 (2013.01); C07D 401/06 (2013.01); C07D 209/48 (2013.01); C07D 409/06 (2013.01); C07D 209/44 (2013.01); C07D 405/10 (2013.01); A61K 31/438 (2013.01); C07D 413/10 (2013.01); C07D 253/08 (2013.01); A61K 31/53 (2013.01); A61K 31/444 (2013.01); A61K 31/536 (2013.01); A61K 31/506 (2013.01); C07D 403/10 (2013.01); C07D 409/10 (2013.01); A61K 31/4439 (2013.01); A61K 31/4035 (2013.01); A61K 45/06 (2013.01); C07D 409/14 (2013.01); C07D 265/26 (2013.01);
Abstract

The present invention relates to β-hydroxy and amino-substituted carboxylic acids, which act as matrix metalloproteinase inhibitors, particularly diastereomerically pure β-hydroxy carboxylic acids, corresponding processes for their synthesis, and pharmaceutical compositions containing the compounds of the present invention. Compounds of the present invention are useful in the treatment of various inflammatory, autoimmune, and allergic diseases, such as methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, wound healing disorders, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by the over-expression and over-activation of a matrix metalloproteinase.

Find Patent Forward Citations

Loading…